Anbio Biotechnology Class A Ordinary Shares (NNNN) - Total Assets
Based on the latest financial reports, Anbio Biotechnology Class A Ordinary Shares (NNNN) holds total assets worth $32.49 Million USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See NNNN total equity for net asset value and shareholders' equity analysis.
Anbio Biotechnology Class A Ordinary Shares - Total Assets Trend (2021–2024)
This chart illustrates how Anbio Biotechnology Class A Ordinary Shares's total assets have evolved over time, based on quarterly financial data.
Anbio Biotechnology Class A Ordinary Shares - Asset Composition Analysis
Current Asset Composition (December 2024)
Anbio Biotechnology Class A Ordinary Shares's total assets of $32.49 Million consist of 98.0% current assets and 2.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 62.2% |
| Accounts Receivable | $1.06 Million | 5.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how Anbio Biotechnology Class A Ordinary Shares's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see NNNN stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Anbio Biotechnology Class A Ordinary Shares's current assets represent 98.0% of total assets in 2024, a decrease from 100.0% in 2021.
- Cash Position: Cash and equivalents constituted 62.2% of total assets in 2024, down from 85.1% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 5.6% of total assets.
Anbio Biotechnology Class A Ordinary Shares Competitors by Total Assets
Key competitors of Anbio Biotechnology Class A Ordinary Shares based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Gan & Lee Pharmaceuticals Co Ltd
SHG:603087
|
China | CN¥12.14 Billion |
|
Vizionfocus Inc.
TW:4771
|
Taiwan | NT$6.53 Billion |
|
MEDIMI AB AK
F:79T
|
Germany | €1.70 Million |
|
Ansell Ltd
AU:ANN
|
Australia | AU$3.32 Billion |
|
Nanosonics Ltd
AU:NAN
|
Australia | AU$272.48 Million |
|
SDI Ltd
AU:SDI
|
Australia | AU$141.20 Million |
|
Austco Healthcare Ltd
AU:AHC
|
Australia | AU$91.07 Million |
|
Trajan Group Holdings Ltd
AU:TRJ
|
Australia | AU$192.32 Million |
Anbio Biotechnology Class A Ordinary Shares - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 211.10 | 35.56 | 9.88 |
| Quick Ratio | 211.10 | 35.56 | 9.63 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $32.34 Million | $18.24 Million | $12.53 Million |
Anbio Biotechnology Class A Ordinary Shares - Advanced Valuation Insights
This section examines the relationship between Anbio Biotechnology Class A Ordinary Shares's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 41.57 |
| Latest Market Cap to Assets Ratio | 62.49 |
| Asset Growth Rate (YoY) | 19.7% |
| Total Assets | $18.92 Million |
| Market Capitalization | $1.18 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Anbio Biotechnology Class A Ordinary Shares's assets at a significant premium (62.49x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Anbio Biotechnology Class A Ordinary Shares's assets grew by 19.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Anbio Biotechnology Class A Ordinary Shares (2021–2024)
The table below shows the annual total assets of Anbio Biotechnology Class A Ordinary Shares from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $18.92 Million | +19.67% |
| 2023-12-31 | $15.81 Million | +13.28% |
| 2022-12-31 | $13.96 Million | +183.95% |
| 2021-12-31 | $4.92 Million | -- |
About Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcript… Read more